

Please delete the present Abstract of the Disclosure, and substitute the following therefore ---

# ABSTRACT

E1 A method for treating or preventing atherosclerosis in a mammal is described. The use of chimeric constructs comprising PSGL-1 and another molecule for inhibiting the interaction between P-selectin and a ligand of P-selectin is provided. The chimeric construct is administered to a mammal in need of such treatment to cause this inhibition to occur.---

## IN THE CLAIMS:

✓ ✓  
Please cancel claims 45 and 56 without prejudice.  
✓

40. (Four Times Amended) A method for decreasing the formation or growth of atherosclerotic lesions in a mammal comprising:

E2 providing a soluble chimeric construct comprising P-selectin glycoprotein ligand-1 or a fragment thereof and another molecule, said chimeric construct being capable of inhibiting the interaction between P-selectin and a ligand of P-selectin; and

administering to a mammal an effective amount of said chimeric construct such that said P-selectin-ligand interaction is inhibited, wherein said chimeric construct is administered prior to, in conjunction with, or after a vessel-corrective technique.

41. The method of claim 40, wherein said vessel-corrective technique is selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.

49. The method of claim 40, wherein said chimeric construct is administered in sequential exposures over a period of hours, days, weeks, months or years.

50. The method of claim 40, wherein said chimeric construct is administered in combination with other therapeutic agents.

---

51 (Four Times Amended) A method for treating or inhibiting atherosclerosis in a mammal comprising:

E3 providing a soluble chimeric construct comprising P-selectin glycoprotein ligand-1 or a fragment thereof and another molecule, said chimeric construct being capable of inhibiting the interaction between P-selectin and a ligand of P-selectin; and

administering to a mammal an effective amount of said chimeric construct such that said P-selectin-ligand interaction is inhibited, wherein said chimeric construct is administered prior to, in conjunction with, or after a vessel-corrective technique.

---

52. The method of claim 51, wherein said vessel-corrective technique is selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.

59. The method of claim 51, wherein said chimeric construct is administered in sequential exposures over a period of hours, days, weeks, months or years.

60. The method of claim 40, wherein said chimeric construct is administered in combination with other therapeutic agents.

---

73. (Amended) A method for treating restinosis in a mammal to which a vessel-corrective technique is administered comprising:

performing a vessel-corrective technique selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery on a mammal; and

E4 administering to said mammal, prior to, in conjunction with or after said vessel-corrective technique, an effective amount of a soluble chimeric construct comprising P-selectin glycoprotein ligand-1 or a fragment thereof, and another molecule, said chimeric construct being capable of inhibiting the interaction between P-selectin and a ligand of P-selectin, such that the restinosis occurring after said vessel-corrective technique is thereby treated.

74. (Amended) A method for treating restinosis in a mammal, comprising: